Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the target of a large decline in short interest during the month of August. As of August 14th, there was short interest totaling 9,037 shares, a decline of 80.3% from the July 30th total of 45,910 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 42,184 shares, the days-to-cover ratio is presently 0.2 days.

Barinthus Biotherapeutics Price Performance

BRNS stock opened at $0.65 on Wednesday. The stock has a market cap of $26.59 million, a price-to-earnings ratio of -0.63 and a beta of -0.39. The company has a 50 day simple moving average of $0.62 and a 200 day simple moving average of $0.63. Barinthus Biotherapeutics has a 1 year low of $0.51 and a 1 year high of $1.83.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A number of institutional investors have recently modified their holdings of the company. Baird Financial Group Inc. raised its holdings in shares of Barinthus Biotherapeutics by 108.2% in the 2nd quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after acquiring an additional 100,000 shares during the last quarter. Renaissance Technologies LLC lifted its position in Barinthus Biotherapeutics by 115.8% in the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock valued at $100,000 after acquiring an additional 76,800 shares in the last quarter. Finally, Rangeley Capital LLC boosted its stake in Barinthus Biotherapeutics by 88.8% during the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after purchasing an additional 75,024 shares during the last quarter. 25.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Barinthus Biotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $4.00.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.